AUROPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.0
| Stock Code | AUROPHARMA | Market Cap | 70,216 Cr. | Current Price | 1,209 ₹ | High / Low | 1,279 ₹ |
| Stock P/E | 34.7 | Book Value | 369 ₹ | Dividend Yield | 0.33 % | ROCE | 10.8 % |
| ROE | 8.65 % | Face Value | 1.00 ₹ | DMA 50 | 1,178 ₹ | DMA 200 | 1,163 ₹ |
| Chg in FII Hold | -0.26 % | Chg in DII Hold | 0.06 % | PAT Qtr | 581 Cr. | PAT Prev Qtr | 559 Cr. |
| RSI | 56.9 | MACD | 0.83 | Volume | 14,10,968 | Avg Vol 1Wk | 25,96,589 |
| Low price | 994 ₹ | High price | 1,279 ₹ | PEG Ratio | 8.14 | Debt to equity | 0.21 |
| 52w Index | 75.5 % | Qtr Profit Var | 8.16 % | EPS | 34.8 ₹ | Industry PE | 29.1 |
📊 Analysis: AUROPHARMA shows good intraday potential. Current price (₹1,209) is trading above both 50 DMA (₹1,178) and 200 DMA (₹1,163), indicating bullish bias. RSI at 56.9 suggests healthy momentum without being overbought. MACD (0.83) is slightly positive, supporting upward movement. However, intraday volume (14,10,968) is lower than average weekly volume (25,96,589), which may limit sharp moves.
💹 Optimal Buy Price: ₹1,200 – ₹1,215 (near support zone).
🎯 Profit-Taking Levels: ₹1,240 – ₹1,260 (short-term resistance).
🛡️ Stop-Loss: ₹1,185 (below intraday support).
⏱️ Exit Strategy if Already Holding: Exit if price fails to sustain above ₹1,200 with weakening momentum or if RSI dips below 55 intraday. If volume strengthens with price action, partial profit booking near ₹1,250 is advisable.
Positive
- EPS of ₹34.8 supports earnings stability.
- Consistent PAT growth (₹581 Cr vs ₹559 Cr previous quarter).
- Stock trading above both 50 DMA and 200 DMA, showing bullish technical setup.
- 52-week performance strong (75.5% index level).
Limitation
- ROCE (10.8%) and ROE (8.65%) are modest compared to peers.
- High PEG ratio (8.14) indicates overvaluation relative to growth.
- Intraday volume lower than average, limiting breakout potential.
Company Negative News
- FII holdings declined (-0.26%), suggesting reduced foreign investor confidence.
Company Positive News
- DII holdings increased (+0.06%), showing domestic institutional support.
- Quarterly profit growth of 8.16% strengthens fundamentals.
Industry
- Industry P/E at 29.1 indicates sector stability, though AUROPHARMA trades at a premium (34.7).
- Pharma sector remains defensive with steady demand, supporting intraday opportunities.
Conclusion
⚖️ AUROPHARMA is a good candidate for intraday trading today. Technicals favor a bullish bias, supported by consistent profit growth. Best strategy is cautious entry near ₹1,200 with tight stop-loss and profit booking around ₹1,250.